CAR-T cell therapy is a new treatment option for multiple myeloma, a type of blood cancer. Here are key points about it:
- Type of Treatment: It's a form of immunotherapy that helps the body's immune system fight cancer more effectively
- Process:
- T cells are collected from the person with myeloma.
- These T cells Show Full Answer
CAR-T cell therapy is a new treatment option for multiple myeloma, a type of blood cancer. Here are key points about it:
- Type of Treatment: It's a form of immunotherapy that helps the body's immune system fight cancer more effectively.
- Process:
- T cells are collected from the person with myeloma.
- These T cells are genetically modified in a lab to recognize and kill cancer cells.
- The modified T cells are then returned to the person's body through an IV infusion.
- Effectiveness: CAR-T cell therapy can reduce or eliminate signs and symptoms of myeloma, even when other treatments have failed. However, it does not work for everyone, and cancer can sometimes return after treatment.
- Side Effects: Potential side effects include infections, muscle aches, diarrhea, nausea, swelling, fever, cough, headache, and loss of appetite. It's important to discuss these with a healthcare provider.
- Hospital Stay: After receiving CAR-T cell therapy, patients often need to stay in the hospital for several weeks to monitor the treatment's effectiveness and manage any side effects.
- FDA Approval: The U.S. FDA approved a specific type of CAR-T cell therapy for multiple myeloma in March 2021.
- Research: Ongoing studies are exploring new CAR-T cell treatments and combinations with other medications to improve outcomes.
For more detailed information, you can refer to the source: [CAR-T Cell Therapy for Multiple Myeloma: What Is It?](https://www.mymyelomateam.com/resources/car-t-c...).
October 9
Continue with Facebook
Sign up with your email
